Evidence map›Paper›PMID 32460816›Full record

Trial reportBreast cancer research : BCR2020

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.

Hee Jeong Kim, Woo Chul Noh, Eun Sook Lee, Yong Sik Jung, Lee Su Kim, Wonshik Han, Seok Jin Nam, Gyung -Yub Gong, Hwa Jung Kim, Sei Hyun Ahn

2 registry-linked trialsOpen access · goldAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Breast cancer research : BCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 31 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 6 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01622361 phase3unknown statusnot on this map

A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer

TypeinterventionalSponsorAsan Medical CenterRan2012 to 2016Enrolled290ConditionsBreast CancerArmsAdriamycin+Cyclophosphamide>Docetaxel, GnRHa with Tamoxifen
NCT06697938 narecruitingnot on this mapstarted 2024, after this paper: background citation

Neoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study

TypeinterventionalSponsorSichuan Cancer Hospital and Research InstituteRan2024 to 2027Enrolled148ConditionsBreast CancerArmsPreoperative SBRT for the Primary Lesion of Breast Cancer
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 6 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Guideline
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Cytomorphological Disparities in Invasive Breast Cancer Cells following Neoadjuvant Endocrine Therapy and Chemotherapy.Pathobiology : journal of immunopathology, molecular and cellular biology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Hee Jeong KimDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic ro 43 gil, song pa gu, Seoul, 138-736, South Korea.ORCID 0000-0002-4509-953X
Woo Chul NohDepartment of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.
Eun Sook LeeDepartment of Surgery, Center for Breast Cancer, Research and Institute and Hospital, National Cancer Center, Goyang, South Korea.
Yong Sik JungDepartment of Surgery, School of Medicine, Ajou University, Suwon, South Korea.
Lee Su KimDivision of Breast and Endocrine Surgery, Hallym Sacred Heart Hospital, College of Medicine, Hallyum University, Anyang, South Korea.
Wonshik HanDepartment of Surgery and Cancer Research Institute, College of Medicine, Seoul National University, Seoul, South Korea.
Seok Jin NamDepartment of Surgery, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, South Korea.
Gyung -Yub GongDepartment of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Hwa Jung KimDepartment of Preventive Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Sei Hyun AhnDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic ro 43 gil, song pa gu, Seoul, 138-736, South Korea. ahnsh@amc.seoul.kr.
Ulsan College · KRAjou University · KRKorea Institute of Radiological and Medical Sciences · KRNational Cancer Center · KRSamsung Medical Center · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNeoadjuvant endocrine therapy (NET) has demonstrated efficacy in post-menopausal patients with hormone-responsive breast cancer. This trial was designed to compare the efficacy of neoadjuvant chemotherapy (NCT) with NET in pre-menopausal breast cancer. PATIENTS AND

methodsIn this prospective, randomised, phase III study, oestrogen receptor (ER)-positive, HER2-negative, and lymph node-positive pre-menopausal breast cancer patients were recruited from 7 hospitals in South Korea. Enrolled patients were randomly assigned (1:1) to receive 24 weeks of either NCT or NET with goserelin and tamoxifen. The primary purpose was to evaluate the non-inferiority of NET compared to NCT using clinical response, assessed by MRI. Besides, pathological complete response rate (pCR), changes in Ki-67 expression, breast conservation surgery (BCS) rate, and quality of life were included as secondary endpoints.

resultsA total of 187 patients were assigned to receive NCT (n = 95) or NET (n = 92), and 87 patients in each group completed treatments. More NCT patients had complete response or partial response than NET patients using MRI (NCT 83.7% vs. NET 52.9%, 95% CI 17.6-44.0, p < 0.001) and callipers (NCT 83.9% vs. NET 71.3%, 95% CI 0.4-24.9, p = 0.046). Three NCT patients (3.4%) and one NET patient (1.2%) showed pCR (p < 0.005). No difference existed in the conversion rate of BCS (13.8% for NCT vs. 11.5% for NET, p = 0.531) and Ki-67 change (p = 0.114) between the two groups. Nineteen NCT patients had treatment-related grade 3 or worse events compared with none in the NET group.

conclusionsBetter clinical responses were observed in pre-menopausal patients after 24 weeks of NCT compared to those observed after NET.

trial registrationClinicaltrials.gov, NCT01622361. Registration June 19, 2012.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCombined Modality TherapyCyclophosphamideDocetaxelDoxorubicinErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesGoserelinHumansLymph NodesMiddle AgedPremenopausePrognosisCyclophosphamideDocetaxelDoxorubicinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesGoserelinReceptors, EstrogenReceptors, ProgesteroneTrastuzumabBreast cancerClinical responseNeoadjuvant chemotherapyNeoadjuvant endocrine therapyPre-menopausal women

Identifiers

PMID32460816
PMCPMC7251809
OpenAlexW3030529007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.